Grand Pharmaceutical Group (HKG:0512) has completed its phase III clinical trial of GPN00833 and met its clinical endpoint, a Monday bourse filing said.
GPN00833 is an anti-inflammatory and analgesic hormone nanosuspension eye drop.
The study showed a significantly higher percentage of patients with zero anterior chamber cell counts from the eighth to the 15th day post-surgery as compared to patients in the placebo group.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。